Targetting the Kinase PAK1 in Colorectal Cancer

Grant number: 1041831 | Funding period: 2013 - 2016

Completed

Abstract

This project aims to develop a new therapy for colorectal cancer (CRC). We have already demonstrated that a molecule called PAK1 is the master regulator of several intracellular signalling pathways, and is essential for CRC growth and invasion. We now plan to study whether inhibitors that block PAK1 activity can prevent the growth of human CRC cells in the laboratory or their development into tumours in animals.

Related publications (5)

Scholarly works icon

Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine

Kai Wang, Huynh Nhi, Xiao Wang, Graham Baldwin, Mehrdad Nikfarjam, Hong He

2018-01-01

Pancreatic ductal adenocarcinoma (PDA) is one of the major types of cancer that exhibit high mortality worldwide because of the la..

Scholarly works icon

Depletion of p21-activated kinase 1 up-regulates the immune system of APC(Delta 14/ ) mice and inhibits intestinal tumorigenesis

Nhi Huynh, Kai Wang, Mildred Yim, Chelsea J Dumesny, Mauro S Sandrin, Graham S Baldwin, Mehrdad Nikfarjam, Hong He

2017-06-19

BACKGROUND: P21-activated kinase 1 (PAK1) stimulates growth and metastasis of colorectal cancer (CRC) through activation of multip..

Scholarly works icon

Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer

Nhi Huynh, Arthur Shulkes, Graham Baldwin, Hong He

2016-01-01

Cancer stem cells (CSC) are tumorigenic and resistant to chemotherapy. In colorectal cancer (CRC), CSCs have been identified by th..

Scholarly works icon

Glaucarubinone inhibits colorectal cancer growth by suppression of hypoxia-inducible factor 1 alpha and beta-catenin via a p-21 activated kinase 1-dependent pathway

Huynh Nhi, John A Beutler, Arthur Shulkes, Graham S Baldwin, Hong He

2015-01-01

p-21-Activated kinase 1 (PAK1) enhances colorectal cancer (CRC) progression by stimulating Wnt/β-catenin, ERK and AKT pathways. PA..

Scholarly works icon

Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases

Dannel Yeo, Huynh Nhi, John A Beutler, Christopher Christophi, Arthur Shulkes, Graham S Baldwin, Mehrdad Nikfarjam, Hong He

2014-05-01

Pancreatic cancer is one of the most lethal of human malignancies. Nearly 100% cases of pancreatic cancer carry mutations in KRas...

University of Melbourne Researchers